Coreline Soft's 'AVIEW LCS' Fully Applied to All Chest CT Scans at Wonkwang University Hospital

Deployment of AI Lung Cancer Screening Software 'AVIEW LCS'

Coreline Soft's artificial intelligence (AI) software for lung cancer screening, 'AVIEW LCS', has been applied to all chest CT examinations at Wonkwang University Hospital.

Coreline Soft AI lung cancer screening software 'AVIEW LCS' in operation. Coreline Soft

Coreline Soft announced on the 24th that the Department of Radiology at Wonkwang University Hospital has established a safety net for image reading by applying AI-based detection of small nodules to all chest CT scans using its product 'AVIEW LCS'. The company explained that this is a standard operating structure that embeds AI across the entire examination protocol, rather than for specific patient groups.

Jeonbuk Province is a super-aged region with a high proportion of residents aged 65 and older, and therefore a high ratio of high-risk patients for respiratory and cardiovascular diseases. The hospital explained that, by introducing AI, it has supplemented the detection of lesions that are easy to miss, such as small nodules, and improved consistency in image reading.

Changes have also appeared in terms of operational efficiency. By introducing AI-based automatic analysis into the process of cardiac CT analysis, the hospital reduced repetitive work and alleviated bottlenecks in the examination workflow. The hospital evaluated this as an effect of structurally improving its examination processing capacity. This case was presented at the Korean Congress of Radiology (KCR), and follow-up academic validation is underway.

Coreline Soft stated that this application case shows that evaluation criteria for medical AI are shifting from a focus on accuracy to a focus on contribution to hospital operations. The company explained that the software can function as an operational infrastructure that contributes to managing reading risks, improving workforce efficiency, and standardizing patient communication.

AVIEW LCS was recently designated as a new medical technology with deferred evaluation, allowing it to be used as a non-reimbursable service at medical institutions nationwide. Based on the accumulation of real-world usage data and the expansion of its subscription-based revenue model, the company plans to gradually expand the scope of deployment, focusing on regional hub hospitals.

This content was produced with the assistance of AI translation services.